Different modes of inhibition of human adenovirus proteinase, probably a cysteine proteinase, by bovine pancreatic trypsin inhibitor  by Brown, Mark T. et al.
FEBS 17176 FEBS Letters 388 (1996) 233 237 
Different modes of inhibition of human adenovirus proteinase, probably 
a cysteine proteinase, by bovine pancreatic trypsin inhibitor 
Mark T. Brown, William J. McGrath, Diana L. Toledo, Walter F. Mangel* 
Biology Department, Brookhaven National Laboratory, Upton, NY  11973, USA 
Received 13 February 1996; revised version received 20 March 1996 
Abstract The type of proteinase and the nature of the active site 
of the human adenovirus proteinase are unknown. For these 
reasons we produced an inhibitor prof'de of the enzyme. Enzyme 
activity in disrupted virions was inhibited by several serine- 
specific as well as cysteine-specific proteinase inhibitors. Of the 
inhibitors that worked, the most useful potentially in illuminating 
the nature of the active site was bovine pancreatic trypsin 
inhibitor (BPTI), and for this reason we extensively character- 
ized the interaction with BPTI. In disrupted virions, the enzyme 
is irreversibly inhibited by BPTI with a Ki of 35 nM and a ki of 
6.2×10 _4 s -1. One reason enzyme activity is inhibited is that 
BPTI, a basic protein, precipitates the viral DNA, a cofactor of 
enzyme activity. In vitro with purified components, BPTI acts as 
a competitive inhibitor (Ki 2 IJNI) of the recombinant proteinase 
complexed with its l 1-amino-acid cofactor pVIc. The recombi- 
nant endoproteinase is heat labile whereas its ll-amino-acid 
cofactor is heat stable. We estimate there are about 50 molecules 
of proteinase per virus particle. 
Key words." Antiviral therapy; Bovine pancreatic trypsin 
inhibitor; Cysteine proteinase; Virus-coded proteinase 
I. Introduction 
Many animal and plant viruses contain a gene for a 
proteinase whose activity is vital for the synthesis of infectious 
virus (see [1] for a review). These virus-coded proteinases are 
appealing targets for antiviral therapy. Human adenoviruses 
encode a proteinase whose activity is required for the matura- 
tion of infectious virions. Of the 12 major polypeptides from 
which adenovirus virions are assembled, 6 are proteolytically 
processed. Weber [2] isolated a temperature-sensitive mutant 
H2ts-1 (ts-1) of human adenovirus erotype 2 (Ad2) that 
lacks proteinase activity at the nonpermissive temperature. 
Virions of ts-1 assemble at the nonpermissive temperature 
but contain precursor proteins in place of the mature compo- 
nents present in wild-type virus. Such immature virions attach 
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Abbreviations: BPTI, bovine pancreatic trypsin inhibitor; Cbz, benzyl- 
oxycarbonyl; dTdP, 2,2'-dithiodipyridine; DMF, dimethylformamide; 
DMSO, dimethylsulfoxide; DNS-GGACK, dansyl-L-glutarnylglycyl-L- 
arginyl chloromethyl ketone; DTT, dithiothreitol; E-64, L-trans- 
epoxysuccinylleucylamido(4-guanidino)butane; HOAc, acetic acid; 
IAA, iodoacetic acid; pVIc, ll-amino-acid cofactor from the C- 
terminus of virion precursor protein pVI; PAGE, polyacrylamide g l 
electrophoresis; PCMB, p-chloromercuribenzoate; PMSF, phenyl- 
methanesulfonyl fluoride; <Glu, pyroglutamic acid; rEP, recombi- 
nant endoproteinase; SBTI, soybean trypsin inhibitor; SDS, sodium 
dodecyl sulfate; TLCK, L-l-chloro-3-(4-tosylamido)-7-amino-2-hepta- 
none HC1; TPCK, L-l-chloro-3-(4-tosylamido)°4-phenyl-2-butanone; 
ts-1, temperature-sensitive mutant H2ts-1 
to cells but fail to initiate a productive infection [3,4]. The 
mutation in ts-1 was identified as a single base-pair change 
in a 204 codon open reading frame (L3 23-kDa) at the 3' end 
of the L3 family of late messages [5]. The nucleotides in the 
L3 23-kDa open reading frame were cloned into plasmids that 
permitted efficient expression in Escherichia coli [6]. 
Recently, we developed a specific, sensitive and quantitative 
assay for the adenovirus proteinase [7,8]. The assay is based 
upon the observation that the adenovirus proteinase will 
cleave small peptides with sequences that correspond to the 
sequences on the amino-terminal side of the cleavage sites in 
virion precursor proteins. For example, the compound (Leu- 
Arg-Gly-Gly-NH)z-rhodamine is cleaved to Leu-Arg-Gly- 
Gly-NH-rhodamine by the proteinase in disrupted wild-type 
virus; this is accompanied by a 3500-fold increase in fluores- 
cence that is proportional to the amount of proteinase. We 
used this assay to characterize proteinase activity in disrupted 
wild-type virus. We not only showed that when wild-type Ad2 
virus was incubated with the fluorogenic substrate (Leu-Arg- 
Gly-Gly-NH)2-rhodamine, significant hydrolysis was ob- 
served, but when ts-1 virus was incubated with (Leu-Arg- 
Gly-Gly-NH)2-rhodamine, no hydrolysis was observed. Sur- 
prisingly, little or no hydrolysis was observed with purified 
recombinant endoproteinase (rEP) obtained from expression 
of the L3 23-kDa gene in E. coli [8]. However, when ts-1 virus 
and rEP were incubated together with (Leu-Arg-Gly-Gly- 
NH)2-rhodamine, significant hydrolysis of the substrate oc- 
curred. This implied that cofactors may be required for max- 
imal activity. The first cofactor we discovered was the viral 
DNA. If disrupted wild-type virus is treated with DNase, 
proteinase activity is lost but can be restored upon addition 
of Ad2 DNA. A second cofactor was shown to be a plasmin- 
sensitive virion protein which turned out to be the 11-amino- 
acid peptide from the C-terminus of the precursor to virion 
protein VI, pVIc [8,9]. 
Although we know the gene sequence for the proteinase 
activity [10] and have identified two cofactors that allowed 
us to reconstitute full proteinase activity in vitro with purified 
components [8], we do not yet know the type of proteinase or 
the nature of its active site. The DNA sequence of the gene for 
the Ad2 proteinase is not related to DNA sequences from any 
proteinase or protein in the data bases [10]. The inhibitor 
profile of the Ad2 proteinase does not correspond to profiles 
exhibited by classical serine or cysteine proteinases [7,11-16]. 
The adenovirus proteinase was originally thought to be a 
serine proteinase based upon inhibition by diisopropyl f uoro- 
phosphate [11,14,17], but more recent data, also based upon 
inhibitor studies, imply it is probably an unusual cysteine 
proteinase [15,18]. Of the inhibitors we tested that worked, 
the most useful potentially in illuminating the nature of the 
active site of the proteinase is bovine pancreatic trypsin inhib- 
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itor (BPTI). Also, we had plans to convert the reactive-site 
sequence of BPTI from one recognized by trypsin to one 
recognized only by the adenovirus proteinase and to use this 
mutant BPTI as an antiviral agent. For these reasons, we 
undertook a more detailed characterization f the interaction 
of the adenovirus proteinase activity with BPTI. 
2. Mater ials and methods 
2.1. Materials 
Tris, HEPES, dithiothreitol (DTT), 2,2'-dithiodipyridine, bovine 
pancreatic trypsin inhibitor, 5,5'-dithiobis(2-nitrobenzoate) r Ell- 
man's reagent (DTNB), and iodoacetate were purchased from Sigma 
(St. Louis, MO). Sephadex G-10 was bought from Pharmacia LKB 
Biotechnology, Inc. (Piscataway, NJ). All other proteinase inhibitors 
as well as octylglucoside were from Boehringer Mannheim (Indiana- 
polis, IN). The pVIc peptide was obtained from Multiple Peptide 
Systems (San Diego, CA). 
2.2. Preparation of virus 
The growth of HeLa cells, infection by wild-type Ad2 and the 
mutant H2ts-1, and the purification of viruses are described in An- 
derson [6]. To prepare disrupted virus, we dialyzed twice CsCI banded 
virions against 10 mM Tris-HC1 (pH 8.0), 1 mM EDTA and then 
centrifuged the suspension at 100000×g for 1 h. The pellet was then 
either suspended in 10 mM Tris-HCl (pH 6.8) containing 20% (v/v) 
glycerol and, after three 10-s bursts of sonication, was stored at 
-20°C or the pellet was suspended in 10 mM Tris-HC1 (pH 8.0), 
1 mM EDTA and placed in a 56°C water bath for 5 min before being 
stored at -20°C. Virus disrupted by low pH and sonication or by heat 
exhibited similar amounts of proteinase activity. 
2.3. Assay of disrupted virions 
The standard assay was performed at 37°C in 0.8 ml assay buffer 
which contained 0.01 M HEPES (pH 7.5), 0.01 M octylglucoside, 2.5 
mM DTT, 2-5 gM (Leu-Arg-Gly-Gly-NH)2-rhodamine as substrate, 
and the indicated amount of disrupted virus. The increase in fluores- 
cence was measured. The excitation wavelength was 492 nm and the 
emission wavelength was 523 nm, both with a bandwidth of 5 nm. 
The change in fluorescence, AF, is the magnitude of the fluorescence 
from the sample minus the magnitude of the fluorescence of an iden- 
tical solution but not containing virus. From the AF, the number of 
pmol of substrate hydrolyzed was calculated using a molar fluores- 
cence coefficient obtained from a mono-substituted rhodamine deriv- 
ative of known concentration. No more than 5% of the substrate was 
hydrolyzed in any assay. 
2.4. Assays with inhibitors 
Most proteinase inhibitors were dissolved in inhibitor buffer which 
contained 50 mM Tris-HC1 (pH 7.4), 25 mM NaC1 and 10 mM 
octylglucoside. Bestatin was dissolved in methanol and E-64 in 50% 
ethanol. Iodoacetic acid was freshly prepared in 50 mM sodium bi- 
carbonate (pH 9.0). PCMB was dissolved in 10 mM NaOH to a 
concentration of 20 mM. TLCK was dissolved in 1 mM HCI and 
TPCK in absolute thanol. PMSF was added as a solid. Inhibitor 
at the indicated concentration and disrupted virus, 101° particles, 
were incubated in 30 gl of inhibitor buffer for 10 min at 37°C. 
Then, 10 gl of 20 gM (Leu-Arg-Gly-Gly-NH)2-rhodamine was added. 
After 30 min, 30 gl of the reaction were added to 670 gl of inhibitor 
buffer and the increase in fluorescence measured. Control assays lack- 
ing inhibitor contained the same kind and volume of solvent used to 
dissolve the inhibitor. 
2.5. Protein concentration 
Protein concentrations were determined by the BCA protein assay 
from Pierce (Rockford, IL). The concentration f rEP was also ob- 
tained by absorbance with a calculated molar absorbance coefficient 
at 280 nm of 26510 [19]. The concentration f pVIc was determined 
by titration of its cysteine residue with Ellman's reagent and con- 
firmed by quantitative amino acid analysis. The cysteine titration 
was carried out by adding 10 /al of stock pVIc solution to 0.99 ml 
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Fig. I. Competition between bovine pancreatic trypsin inhibitor and 
(Leu-Arg-Gly-Gly-NH)2-rhodamine for the proteinase of disrupted 
wild-type Ad2 virus (A) and determination of the macroscopic (Ki) 
and microscopic (ki) inhibitory constants (B)+ In (A) reaction mix- 
tures contained 0.8 ml assay buffer, 5 gM (Leu-Arg-Gly-Gly-NH)2- 
rhodamine and the following concentrations in gM of BPTI: 0 (O), 
1 (O), 2 ([]) and 4 (11). Reactions were initiated at 25°C by the addi- 
tion of 0.1 ml solutions containing 9.2× 10 l° freshly disrupted virus. 
The increase in fluorescence, AF, was determined at the indicated 
times. In (B) the data in (A) plus additional data obtained at the in- 
dicated concentrations of BPTI were analyzed according to the 
method of Leytus et al. [23]. Tangents to the presteady-state por- 
tions of the curves were calculated, and the natural ogarithm of the 
tangents when plotted versus time yielded a straight line whose 
slope, b, was a pseudo first-order rate constant. A plot of b versus 
the inhibitor concentration yielded the rectangular hyperbola from 
which the inhibitory constants of the Ad2 proteinase listed in Table 
2 were derived. 
containing 0.33 mM DTNB and then monitoring the increase in ab- 
sorbance at 412 nm. The mol SH/mol pVIc was calculated using a 
molar extinction coefficient at 412 nm of 14 150 for thionitrobenzoate 
[20]. 
2.6. Reduction and carboxyamidomethylation of BPTI 
BPTI, 5 mg in 3 ml of 0.1 M ammonium bicarbonate (pH 9.0) 
containing 8 M urea and 10 mM DTT, was incubated at 37°C for 
1.5 h to reduce the 3 disulfide bonds. Then, iodoacetamide to 50 mM 
was added followed by incubation for 2 h at room temperature in the 
dark. The resultant reduced, carboxyamidomethylated BPTI was pur- 
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ified from excess reagents by passage through a Sephadex G-10 col- 
umn equilibrated in 0.3 M acetic acid. The flowthrough was pooled, 
protein concentration determined by the BCA protein assay, and the 
reduced, carboxyamidomethylated BPTI stored at --20°C. 
3. Results and discussion 
3.1. Inhibitor profile 
To determine the type of proteinase present in disrupted 
Ad2 virions, we examined the effect of several proteinase in- 
hibitors under conditions in which both competitive and irre- 
versible inhibition would be observed (Table 1). Disrupted 
virus and inhibitor were preincubated for 10 min at 37°C 
and then (Leu-Arg-Gly-Gly-NH)2-rhodamine was added and 
the amount of proteinase activity determined. Benzamidine, 
bestatin, EDTA,  leupeptin and phosphoramidon had no ef- 
fect. Several classic serine proteinase inhibitors were effective: 
from most efficient to least were DNS-GGACK,  PMSF, 
TPCK, TLCK, SBTI and BPTI. However, some of these com- 
pounds can also inhibit cysteine proteinases [21]. Further- 
more, we observed the inhibition was reversible with DNS- 
GGACK,  PMSF, TPCK, and TLCK if 1 mM DTT was 
added after the incubation with inhibitor but prior to the 
addition of substrate. Several classic cysteine proteinase inhib- 
itors were also effective, the most efficient being iodoacetate, 
dithiodipyridine, and PCMB. Much less inhibition was ob- 
served with E-64. Similar inhibitor profiles have been obtained 
using Ad2 immature proteins as substrates [11-14] or using 
synthetic polypeptides as substrates [15,16]. 
3.2. Bovine pancreatic trypsin inhbitor 
The interaction between BPTI and certain serine protein- 
ases is well characterized. The inhibitory specificity is mainly 
restricted to enzymes with trypsin-like substrate specificity and 
trypsin-like tertiary structures in the vicinity of the active site 
[22]. Chymotrypsin is an exception in that while its substrate 
specificity is different from that of trypsin, its active-site con- 
figuration is similar. Complex formation between BPTI and 
trypsin can be characterized by a perfect fit of the reactive-site 
Table 1 
Effect of proteinase inhibitors on the proteinase activity of disrupted 
Ad2 virions with the substrate (Leu-Arg-Gly-Gly-NH)2-rhodamine ~ 
Inhibitor Relative activity 
None 1.00 
1 mM 2,2'-dithiodipyridine 0.04 
3 ~M E-64 0.32 
1 mM iodoacetate 0.03 
0.5 mM PCMB 0.04 
1 mM DNS-GGACK 0.02 
135 ~tM TLCK 0.41 
284 [.tM TPCK 0.24 
1 mM benzamidine 1.00 
2.2 ktM leupeptin 1.00 
5 mM PMSF 0.19 
85 ktM SBTI 0.68 
22 ktM BPTI 0.69 
1.3 mM bestatin 0.96 
5 mM EDTA 1.10 
5.2 mM phosphoramidon 0.88 
~[7]. 
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Fig. 2. Titration of Ad2 virion proteinase by BPTI. Heat-disrupted 
virus, 4.75× 10 l° (©) or 9.5 × 101° virions ([2), were incubated with 
the indicated concentrations of BPTI in 50 ~tl of 0.01 M HEPES 
(pH 7.5), 0.01 M octylglucoside, and 2.5 mM DTT. After 40 rain at 
37°C, 40 ~tl of each reaction was diluted into 1 ml of the same buf- 
fer but containing 5 laM (Leu-Arg-Gly-Gly-NH)2-rhodamine and 
the increase in fluorescence monitored as a function of time. A con- 
trol was assays (o - - o) of a mixture of 4.75× 10 l° disrupted wild- 
type virus particles and 4.75× 10 a° wild-type virus particles whose 
proteinase activity had been inactivated by heating the virions at 
80°C for 90 s. 
inhibitor residue (a lysine or arginine) in the specificity pocket 
of the enzyme. This results in a stable complex that is in an 
intermediate state between the initial Michaelis-Menten com- 
plex and the tetrahedral transition state. Cleavage of the scis- 
sile bond is hindered by the tight packing of the catalytic 
residues, especially His 57, so that proton transfer, a necessary 
step for acyl-enzyme formation, cannot take place. Because 
the interaction between BPTI and trysin is so well character- 
ized, we decided to characterize further the interaction of 
BPTI with the adenovirus proteinase. Our hope was that the 
studies would reveal the type of proteinase and the nature of 
the active site. 
3.3. Inhibition by BPTI of the virion enzyme 
We quantitatively characterized the interaction of BPTI 
with the Ad2 proteinase activity in the virus particle. Dis- 
rupted virus was incubated with (Leu-Arg-Gly-Gly-NH)2-rho- 
damine and three different concentrations of inhibitor (Fig. 
1A), In the presence of BPT1, the initial change in fluores- 
cence with time was not linear which implied that BPTI was 
not a reversible, competitive inhibitor. After about 40 min, the 
change in fluorescence reached a plateau. Thus BPTI acted as 
an irreversible inhibitor of the Ad2 proteinase. 
We used a theory and experimental method we devised for 
determining individual kinetic constants of fast-acting, irrever- 
sible proteinase inhibitors to characterize the interaction be- 
tween BPTI and the adenovirus proteinase [23]. The theory is 
based upon formal analysis of the case of an irreversible in- 
hibitor competing with a substrate for the active site of a 
proteinase. From the theory, an experimental method was 
devised by which the individual microscopic kinetic constants 
for the interaction can be determined. Using the theory, we 
analyzed the data in Fig. 1A and that from two other inhibi- 
tor concentrations. Tangents to the presteady-state portions 
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of the curves were calculated, and the natural ogarithm of the 
tangents when plotted versus time yielded a straight line 
whose slope was a pseudo first-order rate constant, b. A 
plot of b versus the inhibitor concentration is shown in Fig. 
lB. 
The curve in Fig. 1B is a rectangular hyperbola which in- 
dicates inhibition by BPTI obeys the following reaction se- 
quence: 
E+I& E ' I2  EI' 
where E is the Ad2 proteinase, I is BPTI, E.I is an adsorptive 
enzyme-inhibitor complex, EI' is a stable, enzyme-inhibitor 
complex, Ki is an equilibrium dissociation constant, and ki 
is a first-order ate constant. From the rectangular hyperbola 
in Fig. 1B, values for the inhibitor constants were calculated 
and are shown in the Table 2. The Ki of BPTI with trypsin is 
6 orders of magnitude lower than with the Ad2 proteinase 
activity in the virion. 
3.4. Titration of the amount of proteinase per virion 
Since BPTI is an irreversible inhibitor of the virion protein- 
ase activity, we should be able to use BPTI to titrate the 
number of active proteinase molecules per virion. To do 
this, we incubated three concentrations of disrupted virus par- 
ticles with various concentrations of BPTI and, after 40 min, 
assayed for residual enzyme activity (Fig. 2). Extrapolation to 
the abscissa of the data for the reactions with 4.75 x 101° virus 
particles occurred at 3.2 gM BPTI. Since this corresponds to 
9.64X 1013 molecules of BPTI for total inhibition, this meant 
that there were 9.64 x 1013/4.75 × 10 l° or about 2000 molecules 
of enzyme per virion. Doubling the amount of virus in the 
assay doubled the value extrapolated to on the abscissa, to 6.4 
gM BPTI. 
This number for the amount of enzyme per virion is con- 
siderably higher than the one other estimate. In an attempt at 
quantitative immunoblotting with known standards, the num- 
ber of L3 23-kDa protein molecules per virion was estimated 
to be between 5 and 13 [6]. Therefore, we decided to estimate 
the amount of L3 23-kDa protein indirectly by estimating 
how much free pVIc there is per virion. There are 340 mole- 
cules of pVI per virion [24]. To determine how much free pVIc 
there is per virion, we measured the amount of proteinase 
activity in 1 and 2X 101° virions (Fig. 3A,B) and then meas- 
ured the amount of proteinase activity in the same number of 
virions but after the addition of 2.2 nM rEP. Cofactor activity 
was in excess over the L3 23-kDa protein activity by about 5- 
fold. If one assumes that all of the L3 23-kDa protein in the 
virion are complexed with pVIc in a 1 : 1 ratio [25,26] and that 
after the addition of rEP all pVI molecules become processed 
to pVIc [27], then there are 340/5 = 68 molecules of the L3 23- 
kDa protein per virion. 
Because the titration by BPTI of the amount of proteinase 
per virion was much higher than that obtained by two other 
Table 2 
Comparison of the interaction of bovine pancreatic trypsin inhibitor 
with the Ad2 proteinase and bovine trypsin 
Ki (M) ki (S -1) 
Ad2 proteinase 3.5 x 10 -s 6.2 x 10 -4 
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Fig. 3. Identification of the limiting cofactor for proteinase activity 
in wild-type Ad2 virus and the factor most heat labile. In (A) 1 and 
2x 10 l° virus particles were assayed. In (B) 1 and 2x 10 l° virus par- 
ticles were assayed in the presence of 2.2 nM rEP. In (C) 1 and 
2x 10 l° wild-type virus particles in 10 ~1 of assay buffer were incu- 
bated in a boiling water bath for 5 rain prior to the addition of 
rEP (to 2.2 nM) with the substrate. In (D) 1 and 2x 10 l° virus par- 
ticles were assayed for proteinase activity after the virus was incu- 
bated in a boiling water bath for 5 min. 1 x 10 l° virus particles 
(clear bar); 2 x 10 l° virus particles (solid bar). 
methods, we performed an additional control experiment. We 
repeated the titration experiment but with a mixture of 
4.75× 101° wild-type virus particles and an equal number of 
wild-type virus particles whose proteinase activity had been 
inactivated by heating at 80°C for 90 s. The L3 23-kDa pro- 
tein in the virus particle is heat sensitive (Fig. 3D), although 
pVIc in the virus particle can survive for 5 min in a boiling 
water bath (Fig. 3C). We had expected to see a curve identical 
to that with 4.75×10 l° wild-type virus particles alone. 
Although the line extrapolated to the same point on the ordi- 
nate, it extrapolated to slightly more than twice the BPTI 
concentration on the abscissa (Fig. 2). That the line extrapo- 
lated to the same point on the ordinate indicated the heat- 
inactivated enzyme was indeed inactivated. That the line ex- 
trapolated to double the point on the abscissa indicated that 
BPTI was binding to something other than fully functional 
active sites in the enzyme. 
So far, the experiments with BPTI had yielded results that 
were difficult to interpret. On the one hand, inhibition ap- 
peared to be irreversible with a Ki of 35 nM and a ki of 
6.2×10 -4 s -1. This implied that BPTI was binding to the 
active site. On the other hand, in the experiments with heat- 
inactivated proteinase in disrupted virions, the results implied 
that BPTI was binding to a component in virions other than 
the active-site of the proteinase. Of course, the results could 
be interpreted to indicate that BPTI can bind irreversibly to 
the active-site of heat-inactivated proteinase. 
3.5. Inhibition by BPTI  of the enzyme in vitro 
Because we had been able to reconstitute proteinase activity 
in vitro with purified components, we decided to characterize 
the interaction of BPTI with the enzyme activity in vitro. So, 
we repeated the experiments we had performed with disrupted 
virions, but with rEP, pVIc and the viral DNA. We again 
observed irreversible inhibition of proteinase activity (data 
not shown). However, we noticed that some of the assay solu- 
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Fig. 4. Competitive inhibition by BPTI. In 0.01 M HEPES (pH 7.5) 
and 5 mM octylglucoside were incubated 1 laM rEP and 2 IaM 
pVIc. After 5 min at 37°C, the reactions were diluted 40-fold into 
1 ml of 10 mM HEPES (pH 7.5), 5 mM octylglucoside, and either 
0.5 gM (©), 1.0 gM (e) or 2.0 gM (D) (Leu-Arg-Gly-Gly-NH)2- 
rhodamine, and the indicated concentrations of BPTI, and the in- 
crease in fluorescence monitored as a function of time. The dashed 
line parallel to the abscissa is 1/Vm~x. 
tions were cloudy. After centrifugation, the assay solutions 
became clear. The precipitate contained much of the viral 
DNA.  In hindsight this was to be expected. BPTI is a basic 
protein; its p l  is 10.5 [28]. Addition of  BPTI to 2 gM to a 
solution of rEP, pVIc or Ad2 DNA resulted in cloudiness 
only with the solution of Ad2 DNA.  These observations 
opened the possibility that BPTI inhibits proteinase activity 
by removing the cofactor, the viral DNA,  from solution. If 
this were the case, the type of  inhibition would indeed appear 
irreversible. 
If BPTI inhibits the adenovirus proteinase because it pre- 
cipitates the DNA cofactor, then it should not inhibit the 
activity of rEP-pVIc complexes in the absence of DNA.  How- 
ever, it did, and in this case the type of inhibition was not 
irreversible (data not shown). Therefore, we varied substrate 
and inhibitor concentrations. The data are presented in a 
Dixon plot (Fig. 4). Because the three lines intersected above 
the negative region of the abscissa, the mode of inhibition is 
competitive. Thus, with rEP-pVIc complexes, BPTI is a com- 
petitive inhibitor with a Ki of 2 ~tM. As a control, we reduced 
and carboxyamidomethylated BPTI. Although reduced and 
carboxyamidomethylated BPTI no longer inhibited trypsin, 
it was still a competitive inhibitor of the enzyme activity of 
rEP-pVIc complexes (data not shown). 
How is BPTI acting as a competitive inhibitor? A systemat- 
ic study of the cleavage of octapeptides by the virion enzyme 
and molecular modeling indicated that the main determinants 
of the adenovirus proteinase specificity were the amino acids 
at the P4 position, either Ile, Leu or Met, the P2 position, 
Gly, and the PI' position where the side chain of the amino- 
acid residue must be orientated away from the scissile bond 
[15,16]. Analysis of the sequence of BPTI reveals two potential 
adenovirus proteinase sequence sites: Va134-Trya%Glya6-Gly37 
and Thr54-Cys55-Gly56-Gly57 [22]. Inspection of the structure 
of BPTI reveals one site is just below the reactive-site loop 
and the other at the C-terminus. In both regions, the Gly-Gly 
residues are on the surface of the molecule. If the adenovirus 
proteinase binds to either of these sites, that would render 
BPTI a competitive inhibitor of enzyme activity. We see no 
evidence that BPTI is cleaved upon incubatation with the 
adenovirus proteinase. This was to be expected as one out- 
standing property of BPTI is its uncommon stability to pro- 
teolytic degradation by other proteinsase [22]. BPTI is known 
to have antimicrobial and antiviral activities [29]; the observa- 
tions reported here may be relevent as to how BPTI may 
accomplish this. 
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